Drug Profile
Research programme: skin disorder therapeutics - Kythera
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Kythera Biopharmaceuticals
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Skin disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Skin-disorders in USA
- 01 Oct 2015 Kythera Biopharmaceuticals has been acquired by Allergan
- 15 Jul 2015 Development is ongoing in USA